Lucentis (ranibizumab) is used to treat
macular degeneration. Lucentis is also available as a biosimilar. Biosimilars are biologic drugs that are similar to the original medication with no meaningful differences in effectiveness or safety. The currently approved biosimliars for Lucentis are
cimerli (ranibizumab-eqrn) and
byooviz (ranibizumab-nuna). Lucentis may be covered by your Medicare or insurance plan.
With the Patient Assistance Program from Genentech, you can receive your medication at no cost.
You can save more on select medications with GoodRx Companion. See which medications are eligible.